# MarketBeat.com

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/marketbeatcom
Canonical HTML page: https://getbiobrief.com/entity/marketbeatcom

## Timeline

- **2026-08-14**: Quarterly earnings release — Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
- **2026-08-13**: Q2 earnings released; EPS beats consensus — Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
- **2026-07-29**: Weiss Ratings upgrade — Weiss Ratings upgraded Lantern Pharma from 'sell (e+)' to 'sell (d-)'.
- **2026-07-17**: Weiss Ratings reiterates Sell — Restated a 'sell (e+)' rating on MBRX shares in a research note
- **2026-05-23**: Wall Street Zen rating action — Research note on LTRN reported with conflicting direction across sources (upgrade to hold vs downgrade to sell).
- **2026-05-16**: Wall Street Zen downgrades MBRX — Cut its rating from 'sell' to 'strong sell' in a research note
- **2025-12**: Jane Street Group discloses new MBRX position — Acquired 22,550 shares valued at approximately $75,000 during Q4 2025, per SEC filing, representing about 1.11% of the company

## Recent coverage (3 stories)

### Moleculin's $4.06M Market Cap vs ($1.40) EPS: Pipeline Survival?
2026-08-17 00:56:41 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Full story: https://getbiobrief.com/story/moleculin-4m-market-cap-eps-loss-pipeline-survival

### Lantern Pharma Posts $0.57 Loss, Misses Consensus by $0.19; Sell Rating Stands
2026-08-16 16:14:45 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Full story: https://getbiobrief.com/story/lantern-pharma-clinical-stage-eps-miss

### NexGel $2 Target Means 284.69% Upside Over Bluejay
2026-08-12 16:39:36 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A MarketBeat comparison finds NexGel beats Bluejay Diagnostics on 9 of 13 metrics, with a $2.00 target and 284.69% upside. The biotech lens highlights divergent risk profiles between a diagnostics platform and a biomaterials company.
Full story: https://getbiobrief.com/story/nexgel-nxgl-bluejay-bjdx-biotech-comparison

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.